← Eichor
Condition: Refractory Hepatoblastoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Hepatoblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma
NA · 1 location(s) · Sun Yat-sen University · NCT07188311ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Phase 1/Phase 2 · 4 location(s) · Eureka Therapeutics Inc. · NCT04634357Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05556642Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come
Phase 1 · 5 location(s) · Memorial Sloan Kettering Cancer Center · NCT04928677Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Phase 1 · 1 location(s) · New York Medical College · NCT04308330
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.